原始来源记录
决策级临床试验登记变更
Aardvark 暂停 ARD-101 在 PWS 中的 3 期 HERO 试验
该公司自愿暂停了 ARD-101 的 3 期 HERO 和 OLE 试验的入组和给药，此前在健康志愿者研究中观察到可逆的心脏异常。公司正在与 FDA 合作确定后续步骤，并预计在 2026 年第二季度提供进一步指导。ARD-201 的开发也被暂停。
关键事实
来源摘录
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.